Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
09 mai 2024 07h01 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h01 HE
|
Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at...
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09 avr. 2024 16h35 HE
|
Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
05 mars 2024 16h45 HE
|
Prelude Therapeutics, Inc.
Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
29 févr. 2024 16h05 HE
|
Prelude Therapeutics, Inc.
Prelude Therapeutics' Kris Vaddi and Jane Huang to participate in fireside chat at Barclay's Global Healthcare conference 2024 on March 13 in Miami
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
15 févr. 2024 16h05 HE
|
Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND...
Prelude Therapeutics Announces $25 Million Private Placement
11 déc. 2023 09h34 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a...
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
01 nov. 2023 16h10 HE
|
Prelude Therapeutics, Inc.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
01 nov. 2023 16h05 HE
|
Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
14 oct. 2023 12h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical...